| Followers | 65 |
| Posts | 23733 |
| Boards Moderated | 0 |
| Alias Born | 11/23/2016 |
Monday, January 03, 2022 5:06:02 PM
As per slide 5 of the 2021 Dec Corp Presentation, the probability of succes increases with: Patient selection biomarkers, Higher therapeutic response and Lower variability in the target population.
Anavex are doing work on identifying biomarkers and we will likely see new/additional biomarkers beyond the SIGMAR1 wt and variant gene expression from the analysis of the current trials data incl. the PDD OLE study and gut microbiome.
Subsequently, imo we are likely to see P3 trials selecting patients based on one or more biomarkers. Getting this right in preparation for the upcoming potentially pivotal trials in PD, PDD, Fragile-X and undisclosed indication(s) probably takes time - you don't want to precisely select for the wrong subgroup of patients!
By then the Precision Medicine/Therapeutics approach will become reality. For now Anavex have rightly toned down the website wording and focusing on biomarkers.
Recent AVXL News
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
